Frekil

Name: Frekil
Brand: Frekil

AI Native

Intelligence Layer for Clinical Real World Data (RWD)

Est 2026|Raised $500K

LinkedIn 1K|Website|FTEs 3|HQ San Francisco, California, US

01Competitive Landscape

Narrative analysis

- Potential advantages for Frekil: - If the generated-code approach and sandboxed execution are robust and auditable, this model can streamline review workflows compared with black-box analytics. - Effective automation of OMOP mapping could reduce CDM transformation bottlenecks if it supports a broad range of site-specific cases. - Where alternatives may be stronger: - More established RWE vendors may offer validated regulatory-facing workflows, larger professional services teams, and more extensive third-party compliance packages. - Network-based products (e.g., TriNetX) provide direct access to distributed RWD and feasibility capabilities that tooling-only vendors do not.

Adoption trends / market evidence

Public evidence for Frekil is limited. Association with a startup accelerator and a small team size indicate an early-stage vendor that may be in initial commercial scaling.

	Frekil	Atropos Health	TriNetX
Starting Price	Vendor-provided quote-based pricing	Vendor-provided quote-based pricing	Vendor-provided quote-based pricing that varies by institution/use
Primary Use Case	Automation of OMOP harmonization plus protocol/SAP/code generation and TFL production (vendor positioning)	Rapid RWE reporting with packaged delivery capabilities	Feasibility, cohort discovery, multi-institutional RWD access and analytics
Key Strength	Conceptual end-to-end approach emphasizing generated code and a sandbox execution model (vendor claims)	Emphasis on rapid evidence delivery and integration with clinical workflows (vendor materials)	Established network presence; widely used in academic and health-system contexts
Key Weakness	Limited independent reviews; unclear maturity and security attestations; mixed public positioning between RWE and imaging annotation	Vendor-reported metrics may be self-reported and governance/price considerations apply	Data access costs and institutional onboarding complexity; analytics constrained by network model

01Competitive Landscape

Narrative analysis

Potential advantages for Frekil:
- If the generated-code approach and sandboxed execution are robust and auditable, this model can streamline review workflows compared with black-box analytics.
- Effective automation of OMOP mapping could reduce CDM transformation bottlenecks if it supports a broad range of site-specific cases.
Where alternatives may be stronger:
- More established RWE vendors may offer validated regulatory-facing workflows, larger professional services teams, and more extensive third-party compliance packages.
- Network-based products (e.g., TriNetX) provide direct access to distributed RWD and feasibility capabilities that tooling-only vendors do not.

Adoption trends / market evidence

Public evidence for Frekil is limited. Association with a startup accelerator and a small team size indicate an early-stage vendor that may be in initial commercial scaling.

	Frekil	Atropos Health	TriNetX
Starting Price	Vendor-provided quote-based pricing	Vendor-provided quote-based pricing	Vendor-provided quote-based pricing that varies by institution/use
Primary Use Case	Automation of OMOP harmonization plus protocol/SAP/code generation and TFL production (vendor positioning)	Rapid RWE reporting with packaged delivery capabilities	Feasibility, cohort discovery, multi-institutional RWD access and analytics
Key Strength	Conceptual end-to-end approach emphasizing generated code and a sandbox execution model (vendor claims)	Emphasis on rapid evidence delivery and integration with clinical workflows (vendor materials)	Established network presence; widely used in academic and health-system contexts
Key Weakness	Limited independent reviews; unclear maturity and security attestations; mixed public positioning between RWE and imaging annotation	Vendor-reported metrics may be self-reported and governance/price considerations apply	Data access costs and institutional onboarding complexity; analytics constrained by network model

Frekil

01Competitive Landscape

Narrative analysis

Adoption trends / market evidence

02Market Map

01Competitive Landscape

Narrative analysis

Adoption trends / market evidence

02Market Map